Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody

Background To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody. Method Overall, 229 IMN patients were retrospectively collected in this study and classified into anti-PLA2R antibody-nega...

Full description

Bibliographic Details
Main Authors: Wenkai Guo, Yan Zhang, Caifeng Gao, Jing Huang, Jiatong Li, Rong Wang, Bing Chen
Format: Article
Language:English
Published: PeerJ Inc. 2020-02-01
Series:PeerJ
Subjects:
Online Access:https://peerj.com/articles/8650.pdf
id doaj-aee6c40255414eefb1861889975d391e
record_format Article
spelling doaj-aee6c40255414eefb1861889975d391e2020-11-25T01:20:46ZengPeerJ Inc.PeerJ2167-83592020-02-018e865010.7717/peerj.8650Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibodyWenkai Guo0Yan Zhang1Caifeng Gao2Jing Huang3Jiatong Li4Rong Wang5Bing Chen6Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, ChinaDepartment of Nephrology, Yantai Yuhuangding Hospital, School of Medicine, Qingdao University, Yantai, Shandong, ChinaDepartment of Nephrology, Jinan Shizhong People’s Hospital, Jinan, Shandong, ChinaDepartment of Nephrology, Jinan Shizhong People’s Hospital, Jinan, Shandong, ChinaDepartment of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, ChinaDepartment of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, ChinaDepartment of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, ChinaBackground To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody. Method Overall, 229 IMN patients were retrospectively collected in this study and classified into anti-PLA2R antibody-negative (PLA2R−, 59 cases) and antibody-positive (PLA2R+, 170 cases) groups. The clinical and pathological features of the PLA2R− group were analyzed; 162 patients in both groups were followed up, and the PLA2R antigen was detected in renal biopsies from the PLA2R− group. Kaplan-Meier and survival analyses were used to compare differences in prognosis. Results Serum albumin levels were higher and 24-hour urine protein, creatinine, and beta 2-microglobulin (BMG) levels were lower in the PLA2R− group than in the PLA2R+ group; the proportion of acute and chronic tubular lesions was also significantly lower in the PLA2R− group than in in the PLA2R+ group. After treatment, the remission rate was significantly higher in the negative group than in the positive group (93.02% vs 74.78%,), especially the rate of complete remission (51.16% vs 23.47%). Furthermore, the PLA2R antigen-positive staining rate of 43 patients in the PLA2R− group was 62.79%. Although not significant, the survival rate was higher in the PLA2R− group than in the PLA2R+ group. BMG, 24-hour urine protein and acute and chronic tubular lesions were risk factors for kidney death, and 24-hour urine protein was an independent risk factor for kidney death. Conclusions Compared with the PLA2R+ group, the PLA2R− group had mild clinical manifestations and pathological damage and a higher clinical treatment remission rate. Renal tissue PLA2R antigen testing can be considered for patients with seronegative IMN to increase the diagnostic rate.https://peerj.com/articles/8650.pdf Serum phospholipase A2 receptorIdiopathic membranous nephropathyCyclophosphamideCalcineurin inhibitorRemission rate
collection DOAJ
language English
format Article
sources DOAJ
author Wenkai Guo
Yan Zhang
Caifeng Gao
Jing Huang
Jiatong Li
Rong Wang
Bing Chen
spellingShingle Wenkai Guo
Yan Zhang
Caifeng Gao
Jing Huang
Jiatong Li
Rong Wang
Bing Chen
Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
PeerJ
Serum phospholipase A2 receptor
Idiopathic membranous nephropathy
Cyclophosphamide
Calcineurin inhibitor
Remission rate
author_facet Wenkai Guo
Yan Zhang
Caifeng Gao
Jing Huang
Jiatong Li
Rong Wang
Bing Chen
author_sort Wenkai Guo
title Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
title_short Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
title_full Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
title_fullStr Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
title_full_unstemmed Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
title_sort retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase a2 receptor antibody
publisher PeerJ Inc.
series PeerJ
issn 2167-8359
publishDate 2020-02-01
description Background To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody. Method Overall, 229 IMN patients were retrospectively collected in this study and classified into anti-PLA2R antibody-negative (PLA2R−, 59 cases) and antibody-positive (PLA2R+, 170 cases) groups. The clinical and pathological features of the PLA2R− group were analyzed; 162 patients in both groups were followed up, and the PLA2R antigen was detected in renal biopsies from the PLA2R− group. Kaplan-Meier and survival analyses were used to compare differences in prognosis. Results Serum albumin levels were higher and 24-hour urine protein, creatinine, and beta 2-microglobulin (BMG) levels were lower in the PLA2R− group than in the PLA2R+ group; the proportion of acute and chronic tubular lesions was also significantly lower in the PLA2R− group than in in the PLA2R+ group. After treatment, the remission rate was significantly higher in the negative group than in the positive group (93.02% vs 74.78%,), especially the rate of complete remission (51.16% vs 23.47%). Furthermore, the PLA2R antigen-positive staining rate of 43 patients in the PLA2R− group was 62.79%. Although not significant, the survival rate was higher in the PLA2R− group than in the PLA2R+ group. BMG, 24-hour urine protein and acute and chronic tubular lesions were risk factors for kidney death, and 24-hour urine protein was an independent risk factor for kidney death. Conclusions Compared with the PLA2R+ group, the PLA2R− group had mild clinical manifestations and pathological damage and a higher clinical treatment remission rate. Renal tissue PLA2R antigen testing can be considered for patients with seronegative IMN to increase the diagnostic rate.
topic Serum phospholipase A2 receptor
Idiopathic membranous nephropathy
Cyclophosphamide
Calcineurin inhibitor
Remission rate
url https://peerj.com/articles/8650.pdf
work_keys_str_mv AT wenkaiguo retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
AT yanzhang retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
AT caifenggao retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
AT jinghuang retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
AT jiatongli retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
AT rongwang retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
AT bingchen retrospectivestudyclinicopathologicalfeaturesandprognosisofidiopathicmembranousnephropathywithseronegativeantiphospholipasea2receptorantibody
_version_ 1725132178247909376